AZN AstraZeneca PLC

174.96USD1777.50 SEK · STO-2.52%Mkt Cap: 271.35B USDP/E: 26.55

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza,…

Institutional holders20 on file

Key Statistics

Company
Market Cap271.35B USD
Enterprise Value273.94B USD
Revenue (TTM)62.38B USD
Gross Profit48.11B USD
Net Income (TTM)10.22B USD
Revenue/Share40.25 USD
Last Price174.96 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees96.1K
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - General
ISINGB0009895292
Valuation
P/E (Trailing)26.55
P/E (Forward)17.60
PEG1.30
EV/EBITDA130.79
EV/Revenue4.39
P/S44.19
P/B53.30
EPS (TTM)66.96 USD
EPS (Forward)101.02 USD
52W Range
144.4068% of range189.53
52W High189.53 USD
52W Low144.40 USD
Profitability
Gross Margin81.90%
Oper. Margin25.80%
EBITDA Margin34.11%
Profit Margin17.41%
ROE21.01%
ROA8.96%
ROIC15.24%
ROCE15.97%
Growth
Revenue Growth6.70%
Earnings Growth23.50%
Cash Flow & Leverage
Operating CF14.57B USD
CapEx (TTM)5.91B USD
FCF Margin9.02%
FCF Yield2.07%
Net Debt26.16B USD
Net Debt/EBITDA1.23
Net Debt/FCF4.65
Balance Sheet
Debt/Equity0.60
Current Ratio1.01
Quick Ratio0.79
Book Value/Sh33.35 USD
Cash/Share5.26 USD
Dividends
Fwd Div Rate2.98 USD
Trail. Div Rate0.32 USD
Div. Yield1.66%
5Y Avg Yield2.01%
Payout Ratio45.38%
Ex-Div DateAug 6, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)210.73 USD
Upside (mean)+20.4%
Target Range207.60 USD – 214.44 USD
207.60+20.4% to mean214.44
# Analysts3
Ownership
Shares Out.1.55B
Float1.54B
Insiders0.05%
Institutions67.38%
Technical
SMA 50166.18 (+5.3%)
SMA 200168.76 (+3.7%)
Beta0.15
S&P 52W Chg12.00%
Avg Vol (30d)462.33K
Avg Vol (10d)435.68K
Technical Indicators
RSI (14)50.8
MACD43.3090
MACD Signal52.3908
MACD Hist.-9.0818
BB Upper189.77 USD
BB Middle177.33 USD
BB Lower164.89 USD
BB Width14.03%
ATR (14)3.796 USD
Vol Ratio (20d)0.79x

About AstraZeneca (STO: AZN)

›

AstraZeneca (STO: AZN) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 96,100 employees.

The shares were at 1777.50 SEK on 19 November 2026, up 6.3% over 52 weeks. Its 52-week range is 1467.00 SEK to 1925.50 SEK: the price is 7.7% below the high and 21.2% above the low.

At a market capitalisation of 2.76T SEK, it trades at 26.5 times trailing earnings and 17.6 times forward earnings. The median trailing P/E of its 18 largest Drug Manufacturers - General peers is 25.7, so AZN is valued in line with them. It pays a dividend yielding 1.66% (it pays out 45% of its earnings), against a median of 2.81% among the dividend payers in that peer group.

AstraZeneca reports return on equity of 21.0%, an operating margin of 25.8% and revenue up 6.7% year over year.

Its debt exceeds its cash by 26.16B USD, a debt-to-equity ratio of 0.60. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 3 analysts cover the stock; their mean price target of 2140.95 SEK is 20.4% above the current price. The next earnings report is expected on 9 February 2027.